Semaglutide Cut Biological Age by Up to 7 Years in 32-Week HIV Study
Updated
Updated · KTVU FOX 2 San Francisco · Jul 26
Semaglutide Cut Biological Age by Up to 7 Years in 32-Week HIV Study
1 articles · Updated · KTVU FOX 2 San Francisco · Jul 26
Summary
A UC San Diego study found semaglutide users showed a 2- to 7-year reduction in biological aging versus nonusers after 32 weeks.
Researchers tracked people living with HIV—who face elevated inflammation and chronic-disease risk as they age—using epigenetic clocks that measure DNA changes linked to aging speed.
Dr. Suneil Koliwad said the result may reflect GLP-1 drugs' anti-inflammatory effects, extending their potential benefit beyond weight loss, diabetes and cardiovascular risk reduction.
The findings come as at least 1 in 10 Americans now use a GLP-1 drug, though doctors still advise resistance training and adequate protein to limit lean-mass loss during treatment.